Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor

• Published in: Clinical cancer research Vol. 10; no. 3; pp. 909 - 915
• Main Authors: HANDE, Kenneth R, COLLIER, Mary, PARADISO, Linda, STUART-SMITH, Jill, DIXON, Mary, CLENDENINN, Neil, YEUN, Geoff, ALBERTI, Donna, BINGER, Kim, WILDING, George
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.02.2004
• Subjects: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase - metabolism; Antineoplastic agents; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Area Under Curve; Biological and medical sciences; Disease Progression; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - therapeutic use; Female; Humans; Kinetics; Male; Matrix Metalloproteinase Inhibitors; Maximum Tolerated Dose; Medical sciences; Middle Aged; Organic Chemicals - pharmacokinetics; Organic Chemicals - pharmacology; Organic Chemicals - therapeutic use; Pharmacology. Drug treatments; Time Factors; Tumors; Peptidases; Enzyme; Phase I trial; Enzyme inhibitor; Hydrolases; Metalloendopeptidases; Pharmacokinetics; Prinomastat

Purpose: Prinomastat is a matrix metalloprotease (MMP) inhibitor with selectivity for MMPs 2, 3, 9, 13, and 14. Inhibition of these MMPs has been postulated to block tumor invasion and metastasis. This Phase I, dose-escalation study was designed to evaluate the acute and chronic toxicities of variou...